摘要
目前,多发性硬化症(MS)的病因及其发病机制尚未清楚。RIG-Ⅰ样受体(RLRs)是新发现的一类模式识别受体(PRRs),位于细胞质内,可识别病毒双链RNA的解旋酶,并通过自身的半胱天冬酶活化募集结构域(CARD)与干扰素β启动刺激因子(IPS)-1发生相互作用,形成IPS-1信号小体,诱导干扰素Ⅰ型(Ⅰ-IFN)的表达,从而启动免疫应答以及诱导抗病毒反应。研究发现,缺乏IPS-1的小鼠疾病将继续恶化,伴随高炎症反应,从而加重轴突损伤和脱髓鞘病变。此外,若启动免疫细胞上的RLRs,能缓解MS小鼠的炎症并预防髓鞘的断裂,从而降低麻痹的发生率。本文就RLRs治疗MS的研究进展进行综述。
At present, the etiology and pathogenesis of multiple sclerosis are unclear. RIG- I -like receptors are a new- ly discovered pattern recognition receptors （RLRs）, which are located in cytoplasm. They can recognize the helicase of viral dsRNAs, and interact with interferon beta promoter stimulator （IPS）- 1 through their caspase activation recruitment domain （CARD）, then form IPS- 1 signalsome and induce the expression of interferon type I （ I -IFN）, thereby initiate innate im- mune response and induce antiviral response. Recent studies have found that mice lacking IPS-1 would develop exacerbated disease and accompanied by markedly higher inflammation, increasing axonal damage and demyelination. Furthermore, initi- ating the RIG- I -like helicase receptor on the immune cells can alleviate inflammation and myelin fracture in multiple scle- rosis of mouse model, thus limit the incidence of paralysis. This paper is a review about the research progress on RLRs in the treatment of multiple sclerosis.
出处
《天津医药》
CAS
2016年第1期117-120,共4页
Tianjin Medical Journal
基金
国家自然科学基金资助项目(81360074)
